Cargando…
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the cancers with the highest morbidity and mortality. Sorafenib used to be the main treatment for unresectable HCC patients. However, regimens based on immune checkpoint inhibitors (ICIs) have attracted attention in recent years because of their r...
Autores principales: | Lei, Qing, Yan, Xin, Zou, Huimin, Jiang, Yixuan, Lai, Yunfeng, Ung, Carolina Oi Lam, Hu, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519826/ https://www.ncbi.nlm.nih.gov/pubmed/36171533 http://dx.doi.org/10.1007/s12672-022-00559-1 |
Ejemplares similares
-
Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis
por: Zou, Huimin, et al.
Publicado: (2022) -
Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis
por: Yan, Xin, et al.
Publicado: (2022) -
Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma
por: Zou, Huimin, et al.
Publicado: (2023) -
Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021) -
Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review
por: Zou, Huimin, et al.
Publicado: (2022)